Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHorowitz, M.en
dc.contributor.authorFlint, A.en
dc.contributor.authorJones, K.en
dc.contributor.authorHindsberger, C.en
dc.contributor.authorRasmussen, M.en
dc.contributor.authorKapitza, C.en
dc.contributor.authorDoran, S.en
dc.contributor.authorJax, T.en
dc.contributor.authorZdravkovic, M.en
dc.contributor.authorChapman, I.en
dc.identifier.citationDiabetes Research and Clinical Practice, 2012; 97(2):258-266en
dc.description.abstractAIMS: Liraglutide reduces bodyweight in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the mechanisms underlying this effect. METHODS: The comparative effects of liraglutide, glimepiride and placebo on energy intake, appetite, nausea, gastric emptying, antral distension, bodyweight, gastrointestinal hormones, fasting plasma glucose and resting energy expenditure (REE), were assessed in subjects with T2DM randomised to treatment A (liraglutide-placebo), B (placebo-glimepiride) or C (glimepiride-liraglutide). Assessments were performed at the end of each 4-week treatment period. RESULTS: Energy intake was less (NS) with liraglutide vs placebo and glimepiride, and 24-h REE was higher (NS) with liraglutide vs placebo and glimepiride. Fasting hunger was less (p=0.01) with liraglutide vs placebo and glimepiride, and meal duration was shorter with liraglutide (p=0.002) vs placebo. Paracetamol AUC(0-60 min) and C(max) were less (p<0.01) and fasting peptide YY was lower (p ≤ 0.001) after liraglutide vs placebo and glimepiride. Bodyweight reductions of 1.3 and 2.0 kg were observed with liraglutide vs placebo and glimepiride (p<0.001). There were no differences on antral distension, nausea, or other gastro-intestinal hormones. CONCLUSION: Liraglutide caused decreased gastric emptying and increased reduction in bodyweight. The mechanisms of the liraglutide-induced weight-loss may involve a combined effect on energy intake and energy expenditure.en
dc.description.statementofresponsibilityMichael Horowitz, Anne Flint, Karen L. Jones, Charlotte Hindsberger, Mads F. Rasmussen, Christoph Kapitza, Selena Doran, Thomas Jax, Milan Zdravkovic, Ian M. Chapmanen
dc.publisherElsevier Sci Ireland Ltden
dc.rightsCopyright © 2012 Elsevier Ireland Ltd. All rights reserved.en
dc.subjectLiraglutide; Glucagon-like peptide-1; Appetite; Energy intake; Gastric emptyingen
dc.titleEffect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetesen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.